References
- Güçlü M, Ağan AF. Relationship of peripheral blood neutrophil to lymphocyte ratio and irritable bowel syndrome. Turkish J Med Sci. 2017;47(4):1067–1071.
- Manzoli L, Flacco ME, Marzuillo C, et al. Prevalence of severe irritable bowel syndrome among Italian adults. A meta-analysis. Eur Rev Med Pharmacol Sci. 2017;21(24):5751–5764.
- Geijo-Martínez F, Sánchez-Garrido A, Marcos-Prieto H, et al. Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome. Rev Esp Enfermedades Dig. 2018;110(7):451–457.
- Alammar N, Stein E. Irritable bowel syndrome. Med Clin North Am [Internet]. 2019 Jan 1 [cited 2019 Apr 16];103(1):137–152. Available from]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30466670
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol [Internet]. 2012 Jul [cited 2019 Apr 15];10(7):712–721.e4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1542356512003084
- Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol [Internet]. 2017;112(5):763–774. DOI:10.1038/ajg.2017.41
- Pourmasoumi M, Ghiasvand R, Darvishi L, et al. Comparison and assessment of flixweed and fig effects on irritable bowel syndrome with predominant constipation: a single-blind randomized clinical trial. Explore [Internet]. 2018. DOI:10.1016/j.explore.2018.09.003
- Kosako M, Akiho H, Miwa H, et al. Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey. Biopsychosoc Med. 2018;12(1):1–11.
- Zielińska A, Sałaga M, Włodarczyk M, et al. Chronic abdominal pain in irritable bowel syndrome – current and future therapies. Expert Rev Clin Pharmacol [Internet]. 2018 Jul 3 [cited 2019 Apr 15];11(7):729–739. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29957084
- Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil Internet]. 2017 Apr 30 [cited 2019 Apr 15];23(2):151–163. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28274109
- Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol [Internet]. 1997 Jan 8 [cited 2019 Apr 15];32(9):920–924. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9299672
- Miner PB. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. Expert Opin Pharmacother [Internet]. 2018;19(2):177–183. DOI:10.1080/14656566.2018.1427733
- Belsey J, Greenfield S, Candy D, et al. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther [Internet]. 2010 Feb [cited 2019 Apr 15];31(9):938–949. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20180788
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol [Internet]. 2016 Oct 1 [cited 2018 Mar 16];1(2):133–146. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28404070
- Gershon MD, Wade PR, Kirchgessner AL, et al. 5-HT receptor subtypes outside the central nervous system. Roles in the physiology of the gut. Neuropsychopharmacology [Internet]. [cited 2019 Apr 15];3(5–6):385–395. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2078274
- Thijssen AY, Mujagic Z, Jonkers DMAE, et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2016 Jan [cited 2019 Apr 15];43(2):272–282. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26538292
- Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology [Internet]. 2006 Jan [cited 2019 Apr 15];130(1):34–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16401466
- Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol [Internet]. 2005 Apr [cited 2019 Apr 15];3(4):349–357. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15822040
- Lee C, Doo E, Choi JM, et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis. J Neurogastroenterol Motil. 2017;23(3):349–362.
- Popa SL, Leucuta DC, Dumitrascu DL. Pressure management as an occupational stress risk factor in irritable bowel syndrome: a cross-sectional study. Medicine (Baltimore). 2018;97(49):e13562.
- Rao SSC, Yu S, Fedewa A. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41(12):1256–1270.
- Ghoshal UC. Chronic constipation in Rome IV era: the Indian perspective. Indian J Gastroenterol. 2017;36(3):163–173.
- Moayyedi P, Quigley EMM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol [Internet]. 2014 Sep [cited 2019 Apr 15];109(9):1367–1374. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25070054
- Ng QX, Soh AYS, Loke W, et al. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res [Internet]. 2018 [cited 2019 Jul 9];11:345–349. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30288077
- Dlugosz A, Zakikhany K, Acevedo N, et al. Increased expression of toll-like receptors 4, 5, and 9 in small bowel mucosa from patients with irritable bowel syndrome. Biomed Res Int. 2017;2017:1–7.
- Gribar SC, Anand RJ, Sodhi CP, et al. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol [Internet]. 2008 Mar 1 [cited 2019 Apr 15];83(3):493–498. DOI:10.1189/jlb.0607358
- Beyder A, Mazzone A, Strege PR, et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology [Internet]. 2014 Jun [cited 2019 Apr 15];146(7):1659–1668. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508514002972
- Zucchelli M, Camilleri M, Nixon Andreasson A, et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut [Internet]. 2011 Dec 1 [cited 2019 Apr 15];60(12):1671–1677. DOI:10.1136/gut.2011.241877
- Ramsden C, Gagnon C, Graciosa J, et al. Do omega-6 and trans fatty acids play a role in complex regional pain syndrome? A pilot study. Pain Med [Internet]. 2010 Jul 1 [cited 2019 Apr 16];11(7):1115–1125. DOI:10.1111/j.1526-4637.2010.00882.x
- Bautzova T, Hockley JRF, Perez-Berezo T, et al. 5-oxoETE triggers nociception in constipation-predominant irritable bowel syndrome through MAS-related G protein–coupled receptor D. Sci Signal. 2018;11(561):eaal2171.
- Mosińska P, Salaga M, Fichna J. Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. Expert Opin Investig Drugs [Internet]. 2016 Mar 3 [cited 2019 Jul 9];25(3):275–286. DOI:10.1517/13543784.2016.1142532
- Shin A, Camilleri M, Vijayvargiya P, et al. Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol [Internet]. 2013 Oct [cited 2019 Apr 15];11(10):1270–1275.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23639599
- Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol [Internet]. 2012 Sep [cited 2019 Apr 15];10(9):1009–1015.e3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1542356512005216
- Hubert S, Chadwick A, Wacher V, et al. Development of a modified-release formulation of lovastatin targeted to intestinal methanogens implicated in irritable bowel syndrome with constipation. J Pharm Sci [Internet]. 2018 Feb 1 [cited 2019 Jul 12];107(2):662–671. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28989013
- Gottlieb K, Wacher V, Sliman J, et al. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther [Internet]. 2016 Jan [cited 2019 Jul 9];43(2):197–212. DOI:10.1111/apt.13469
- Marsh E, Morales W, Chua K, et al. Undefined. Lovastatin lactone inhibits methane production in human stool homogenates. content.stockpr.com [Internet]. 2015 [cited 2019 Jul 9]. Available from: http://content.stockpr.com/syntheticbiologics/db/220/608/file/Lovastatin+in+Human+Stool-FINAL+Poster+(ACG+2015).pdf
- El-Salhy M, Gundersen D, Gilja OH, et al. Is irritable bowel syndrome an organic disorder? World J Gastroenterol [Internet]. 2014 Jan 14 [cited 2019 Jul 12];20(2):384. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24574708
- Serra J, Salvioli B, Azpiroz F, et al. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology [Internet]. 2002 Sep [cited 2019 Jul 12];123(3):700–706. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12198695
- Dupont AW, Jiang ZD, Harold SA, et al. Motility abnormalities in irritable bowel syndrome. Digestion. 2014;89(2):119–123.
- Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus. 2016;5(1):1–8.
- Malinen E, Rinttilä T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol. 2005;100(2):373–382.
- Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut [Internet]. 2013 Jan [cited 2019 Jul 12];62(1):159–176. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22730468
- Nourrisson C, Scanzi J, Pereira B, et al. Blastocystis is associated with decrease of fecal microbiota protective bacteria: comparative analysis between patients with irritable bowel syndrome and control subjects. Ruaux CG, editor. PLoS One [Internet]. 2014 Nov 3 [cited 2019 Jul 12];9(11):e111868. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25365580
- Abrahamsson H, Östlund-Lindqvist A-M, Nilsson R, et al. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol Internet]. 2008 Jan 8 [cited 2019 Jul 12];43(12):1483–1488. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18788050
- Zelnorm single patient IND packet [Internet]. [ cited 2019 Jul 14]. Available from: http://www.fda.gov/AboutFDA/ReportsManualsForms/Forms/default.htm
- Layer P, Keller J, Loeffler H, et al. Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. Ther Clin Risk Manag [Internet]. 2007 Mar [cited 2019 Apr 16];3(1):107–118. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18360619
- NDA 021200 S015 Zelnorm (tegaserod) i NDA/BLA multi-disciplinary review and evaluation [Internet]. [ cited 2019 Jul 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/021200Orig1s015MultidisciplineR.pdf
- Marciniak TA, Serebruany V. Should we use tegaserod for irritable bowel syndrome? Am J Ther [Internet]. 2019 Mar 29 [cited 2019 Apr 16];1. Available from: http://insights.ovid.com/crossref?an=00045391-900000000-98474
- FDA briefing document joint meeting of the gastrointestinal drugs advisory committee and drug safety and risk management advisory committees [Internet]. 2018 [cited 2019 Jul 13]. Available from: https://www.fda.gov/media/119011/download
- FDA approves the reintroduction of ZelnormTM (tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65 [Internet]. [ cited 2019 Apr 16]. Available from: https://www.prnewswire.com/news-releases/fda-approves-the-reintroduction-of-zelnorm-tegaserod-for-irritable-bowel-syndrome-with-constipation-ibs-c-in-women-under-65-300821611.html
- Drug approval package. [ cited 2019 Apr 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021908s000_AmitizaTOC.cfm
- Soubra M, Schey R. Lubiprostone for the treatment of adult women with irritable bowel syndrome with constipation. Clin Med Insights Gastroenterol. 2012;5:23–30.
- Wilson N, Schey R. Lubiprostone in constipation: clinical evidence and place in therapy. Ther Adv Chronic Dis. 2015;6:40–50.
- FDA approves linzess to treat certain cases of irritable bowel syndrome and constipation [Internet]. [ cited 2019 Jul 13]. Available from: https://www.drugs.com/newdrugs/fda-approves-linzess-certain-cases-irritable-bowel-syndrome-constipation-3469.html
- Trentacosti AM, He R, Burke LB, et al. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol [Internet]. 2010;105(4):730–734. DOI:10.1038/ajg.2010.12
- Lacy BE, Schey R, Shiff SJ, et al. Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial. PLoS One. 2015;10(7):1–17.
- Synergy pharmaceuticals announces fda approval of trulance (plecanatide) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults [Internet]. [ cited 2019 Jul 15]. Available from: https://www.drugs.com/newdrugs/synergy-pharmaceuticals-announces-fda-approval-trulance-plecanatide-irritable-bowel-syndrome-4685.html
- Sharma A, Herekar AA, Bhagatwala J, et al. Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy. Clin Exp Gastroenterol. 2019;12:31–36.
- SYN-010 :: synthetic biologics, Inc. (SYN) [Internet]. [ cited 2019 Jul 15]. Available from: https://www.syntheticbiologics.com/product-pipeline/syn-010
- Muskal SM, Sliman J, Kokai-Kun J, et al. Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway. F1000Res. 2016;5:606.
- A single-dose, open-label, study to evaluate the sustainability of the effects of SYN-010 in patients with IBS-C - full text view - clinicalTrials.gov [Internet]. [ cited 2019 Apr 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT02493036
- Hellström PM, Hein J, Bytzer P, et al. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther [Internet]. 2009 Jan [cited 2019 Jul 9];29(2):198–206. DOI:10.1111/j.1365-2036.2008.03870.x
- Amato A, Cinci L, Rotondo A, et al. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 2010;22(6):664–672.
- NCT01056107 @ clinicaltrials.gov [Internet]. [cited 2019 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT01056107?term=rose-010&cond=ibs&rank=1
- Camilleri M, Vazquez-Roque M, Iturrino J, et al. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome. Am J Physiol Liver Physiol [Internet]. 2012 Jul [cited 2019 Jul 15];303(1):G120–G128. DOI:10.1152/ajpgi.00076.2012
- Li ZY, Zhang N, Wen S, et al. Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome. Clin Res Hepatol Gastroenterol [Internet]. 2017;41(4):459–465. DOI:10.1016/j.clinre.2016.12.007.
- Rao AS, Wong BS, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology [Internet]. 2010 Nov [cited 2019 Jul 15];139(5):1549–1558.e1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0016508510011479
- NCT00912301 @ clinicaltrials.gov [Internet]. [cited 2019 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT00912301?cond=sodium+chenodeoxycholate&rank=1
- Vijayvargiya P, Camilleri M, Burton D, et al. Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. Aliment Pharmacol Ther [Internet]. 2019 Mar [cited 2019 Jul 15];49(6):744–758. DOI:10.1111/apt.15106.
- Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med [Internet]. 2014 Mar 12 [cited 2019 Jul 15];6(227):227ra36–227ra36. DOI:10.1126/scitranslmed.3007790.
- A study to evaluate the safety and efficacy of RDX5791 for the treatment of constipation predominant irritable bowel syndrome (IBS-C) - full text view - clinicalTrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01340053
- Rosenbaum DP, Yan A, Jacobs JW. Pharmacodynamics, safety, and tolerability of the NHE3 inhibitor tenapanor: two trials in healthy volunteers. Clin Drug Investig Internet]. 2018 Apr 23 [cited 2019 Jul 15];38(4):341–351. DOI:10.1007/s40261-017-0614-0
- The efficacy of AZD1722 in constipation predominant Irritable Bowel Syndrome (IBS-C) - full text view - clinicalTrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01923428
- A 12-week study with a 4-week randomized withdrawal period to evaluate the efficacy and safety of tenapanor for the treatment of IBS-C - full text view - clinicaltrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02621892
- A 26-week study to evaluate the efficacy and safety of tenapanor in IBS-C - full text view - clinicalTrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02686138
- Ardelyx showcases new data from T3MPO-3 long-term safety trial of tenapanor for IBS-C in presidential poster at ACG 2018 annual meeting | Ardelyx, Inc. [Internet]. [ cited 2019 Jul 13]. Available from: http://ir.ardelyx.com/news-releases/news-release-details/ardelyx-showcases-new-data-t3mpo-3-long-term-safety-trial
- Ardelyx submits new drug application for tenapanor for IBS-C [Internet]. [ cited 2019 Jul 13]. Available from: https://www.drugs.com/nda/tenapanor_180913.html
- Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014 Jan 31 [cited 2019 Jul 15];20(1):6–16.
- DDP733. [ cited 2019 Jul 15]. Available from: https://www.drugbank.ca/drugs/DB05049
- Evangelista S. Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Invest Drugs [Internet]. 2007 May [cited 2019 Jul 15];8(5):416–422. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17520871
- Title: Compositions comprising MKC-733 (PUMOSETRAG) useful for treating irritable bowel syndrome [Internet]. 2008 [cited 2019 Apr 16]. Available from: https://www.lens.org/images/patent/WO/2008100422/A1/WO_2008_100422_A1.pdf
- A study to evaluate the safety, tolerability and pharmacodynamics of DDP733 for IBS-c - full text view - clinicaltrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT00215566
- Li ZS, Schmauss C, Cuenca A, et al. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D 2 receptor : analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci. 2006;26(10):2798–2807.
- Yoon S, Lee H, Kim TE, et al. Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. Drug Des Devel Ther. 2014;8:123–128.
- Lim HC, Kim YG, Lim JH, et al. Effect of Itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro. Yonsei Med J. 2019;49(3):472–478.
- Study to evaluate the role of Itopride HCI in patients with irritable bowel syndrome with predominant constipation - full text view - clinicaltrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01027260
- Arneric SP, Holladay M, Williams M. Neuronal nicotinic receptors : a perspective on two decades of drug discovery research. Biochem Pharmacol. 2007;74:1092–1101.
- Dineley KT, Pandya AA, Yakel JL. Nicotinic ACh receptors as therapeutic targets in CNS disorders functional role of nicotinic ACh receptors in the brain. Trends Pharmacol Sci [Internet]. 2015 [cited 2019 Jul 15];36(2):96–108. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324614/pdf/nihms660322.pdf
- Proof-of-principle study of TC-6499 in the treatment of constipation predominant Irritable Bowel Syndrome (IBS) - full text view - clinicaltrials.gov [Internet]. [ cited 2019 Jul 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01149200
- Tack J, Müller-Lissner S, Bytzer P, et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut [Internet]. 2005 [cited 2019 Jul 13];54:1707–1713. Available from: www.gutjnl.com
- ZelnormTM (tegaserod) [Internet]. 2018 [cited 2019 Jul 13]. Available from: https://www.fda.gov/media/119019/download
- Kamuda JA, Candidate P, Mazzola N. Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation. P and T. 2018;43(4):207–210.
- Sodium-chenodeoxycholate @ pubchem.ncbi.nlm.nih.gov [Internet]. [cited 2019 Mar]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-chenodeoxycholate#section=NLM-Curated-PubMed-Citations
- Important precautions. [cited 2019 Sep]. Available from: http://www.meppo.com/pdf/drugs/2845-GANATON-1415104080.pdf. 4–6.
- TC 6499 - AdisInsight [Internet]. [ cited 2019 Oct 17]. Available from: https://adisinsight.springer.com/drugs/800027601
- Pumosetrag hydrochloride; www.chemscene.com [Internet]. [cited 2019 Sep]. Available from: https://www.chemscene.com/194093-42-0.html